Opinion: Reformulating drugs helps profits more than patients
Prescription drug prices remain stubbornly high in the U.S. even though making drugs more affordable is a priority for both Democrats and Republicans. There are many reasons for the lack of progress. Some are deliberate, others are accidental.
A dizzying and byzantine pharmaceutical system with minimal transparency is one part of the problem. Companies’ ability to stymie reform, like not allowing Medicare to negotiate drug prices, is another. So is anti-competitive behavior from drug manufacturers, which games the system at the expense of patient affordability and access to medications.
Read Original Article: Opinion: Reformulating drugs helps profits more than patients »
